Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Epidemiology

Abstract #3033: High frequency of BRCA1 and BRCA2 carriers in premenopausal breast cancer patients unselected for family history: Mutation screening using DNA from paraffin-embedded tissue blocks

Marjanka Schmidt, Annegien Broeks, Richard van Hien, Sten Cornelissen, Renate Udo, Senno Verhoef, Peter Devilee, Rob Tollenaar, Frans Hogervorst, Flora van Leeuwen and Laura Van 't Veer
Marjanka Schmidt
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annegien Broeks
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard van Hien
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sten Cornelissen
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renate Udo
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Senno Verhoef
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Devilee
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob Tollenaar
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frans Hogervorst
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flora van Leeuwen
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Van 't Veer
Netherlands Cancer Instute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Current screening advice for high-risk mutations in BRCA1/2 is based family history of breast cancer or breast cancer development before age 35 years. A significant part of BRCA1/2 carriers may not be detected by these criteria. Additionally, within the Clinical Genetic Centers and in most studies, BRCA1/2 mutations were analyzed in DNA from blood from selected living probands and their (affected) family members. One study so far showed that BRCA1/2 mutations may also play a role in families where breast cancer is not common (King et al, 2003). Data on the proportion of BRCA1 and especially BRCA2 carriers in unselected hospital based series, not biased by survivorship (being alive to provide a blood sample) and selected irrespective of family history, are relatively scarce. We analyzed operable breast cancer patients diagnosed with invasive mamma carcinoma before the age of 50 years, in 10 Dutch hospitals in the period 1973-2002. DNA was isolated from formalin-fixed paraffin-embedded tissue. Based on a nationwide database of BRCA1/2 mutations in counseled Dutch breast cancer families, we chose to analyze the most frequent pathogenic BRCA1 and BRCA2 mutations, i.e., 39 BRCA1 and 41 BRCA2 mutations, capturing 70% of all known Dutch pathogenic BRCA1/2 families. Frame shift mutations were analyzed by fragment length detection: genomic BRCA1/2 fragments (n=22) were amplified with fluorescent-labeled primers in nine multiplex PCR reactions and then pooled and run in one lane on an ABI PRISM 3730 DNA analyzer. Substitutions were detected by the Allelic Discrimination: genomic BRCA1/2 fragments (n=8) were amplified with primers and fluorescent-labeled (\#8216;Taqman\#8217;) probes and run on the ABI PRISM 7500 Real-Time PCR. Suspect mutations were confirmed by direct sequencing. Among 3148 patients analyzed so far 3.3% BRCA1 and 1.1% BRCA2 carriers were detected. The proportion of BRCA1 carriers significantly declined with increasing age (p <0.001), in the youngest age group <30 years of age, 11% of the patients carried a BRCA1 mutation, compared to 1.6% in the oldest age group (45-50 years). In BRCA2 carriers this trend was less clear and not significant, possibly due to small numbers. On the other hand, a similar lack of trend for BRCA2 was observed in familial breast cancer patients counseled at the Clinical Genetic Center at our institute. Accounting for the incomplete screening (70%), the proportion of BRCA1/2 carriers in the cohort of unselected breast cancer patients would even in the age group of 35-40 years still be high (8%). In comparison, with current screening advice, in 25% of the families counseled at clinical genetic centers a BRCA1/2 mutation is found. In future analyses, tumor characteristics will be included for the prediction of BRCA1/2 carriership.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3033.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #3033: High frequency of BRCA1 and BRCA2 carriers in premenopausal breast cancer patients unselected for family history: Mutation screening using DNA from paraffin-embedded tissue blocks
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #3033: High frequency of BRCA1 and BRCA2 carriers in premenopausal breast cancer patients unselected for family history: Mutation screening using DNA from paraffin-embedded tissue blocks
Marjanka Schmidt, Annegien Broeks, Richard van Hien, Sten Cornelissen, Renate Udo, Senno Verhoef, Peter Devilee, Rob Tollenaar, Frans Hogervorst, Flora van Leeuwen and Laura Van 't Veer
Cancer Res May 1 2009 (69) (9 Supplement) 3033;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #3033: High frequency of BRCA1 and BRCA2 carriers in premenopausal breast cancer patients unselected for family history: Mutation screening using DNA from paraffin-embedded tissue blocks
Marjanka Schmidt, Annegien Broeks, Richard van Hien, Sten Cornelissen, Renate Udo, Senno Verhoef, Peter Devilee, Rob Tollenaar, Frans Hogervorst, Flora van Leeuwen and Laura Van 't Veer
Cancer Res May 1 2009 (69) (9 Supplement) 3033;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Epidemiology

  • Abstract SY32-02: Genetic architecture of cancer and other complex diseases: Lessons learned and future directions
  • Abstract SY07-04: Diet and xenobiotic-metabolizing enzymes: Learning from controlled feeding studies in humans
  • Abstract SY08-01: Cancer in immunosuppressed populations: Epidemiologic clues to causation
Show more 3

Candidate Risk Genes: Melanoma, Hereditary Cancer Syndromes, and Rare and Childhood Cancers -- Poster Presentations - Proffered Abstracts

  • Abstract #3048: Variation at KITLG and SPRY4 predispose to testicular germ cell cancer
  • Abstract #3037: Contribution of the Rad50, Mre11 and NBN genes to HBOC
  • Abstract #3032: Classifying BRCA1 ring finger variants
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement